Lundbeck nabs EMA approval for new antidepressant; Celltrion confirms possible stake sale;

@FiercePharma: Top FiercePharma news this AM: Merck to cut 150 jobs from Saphris sales team. Sold drug to Forest last month. Story | Follow @FiercePharma

@EricPFierce: FDA says nada to Lemtrada; will Sanofi be willing to invest in additional trials? Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Tuesday: China suspends imports of Pfizer's antifungal Diflucan on a paperwork problem. Story | Follow @CarlyHFierce

> The Danish drugmaker Lundbeck won European approval for its antidepressant Brintellix, approved in the U.S. in September. Report

> South Korean biosimilars specialist Celltrion confirms that its largest shareholder is in talks to sell a controlling stake in the company. Report

> The Indian pharmaceutical sector is expected to see slower growth in 2014--about 12%--because of pricing pressures, trade issues and FDA enforcement actions. Report

> India's Biocon lost its marketing chief, Rakesh Bamzai, to a new job at the U.S.-based generics maker Mylan ($MYL), which recently bought Agila Specialties, also based in India. Report

> North China Pharmaceutical won regulatory approval to issue up to 252.2 million shares. Report

Medical Device News

@FierceMedDev: Wright ends an up-and-down year on a high note. More | Follow @FierceMedDev

@MarkHFierce: There's time to offer public comment on CMS's reduced payments for BRCA tests, and Myriad plans to speak up. Story | Follow @MarkHFierce

@MichaelGFierce: News from the holidays at FierceMedicalDevices: J&J nears the sale of its Ortho clinical Dx division, and more. Round-up | Follow @MichaelGFierce

@GalenMoore: The United States' global share of biomedical research spending fell from 51% in 2007 to 45% in 2012. Report | Follow @GalenMoore

> Stryker snags a traceable sponge outfit for $120M. More

> Carmat jumps on more good news for its artificial heart. Story

> CareFusion clears hurdles in $500M deal for a GE unit. Article

> Metabolon raises $15M after two recent tie-ups. News

Biotech News

@FierceBiotech: U.S. domination of global biomedical R&D slips as Asian budgets swell. News | Follow @FierceBiotech

@JohnCFierce: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: FDA spurns Sanofi's MS drug Lemtrada on fatally flawed PhIII design. More | Follow @DamianFierce

@EmilyMFierce: A New York Times reporter gets her DNA analyzed by three companies with varying results. Piece from NYT | Follow @EmilyMFierce

> Revance, Dicerna ring out an IPO boom year with $155M in pitches. More

> FDA lifts a partial hold on Cell Therapeutics' leukemia drug. Story

> NVCA starts 2014 with a hopeful wrap-up on the biotech IPO party. News

Pharma Manufacturing News

> J&J moves forward with its plan to make Doxil in part of the closed Ben Venue plant. More

> Hospira's India plant disappoints the FDA again. Story

> China takes aim at poor-quality drug production. More

> Baxter initiates a 4-country recall after particulate is found in solutions. News

> Transfer of GSK plant to Aspen Pharmacare will wait until midyear. Report

> $100M fund outlined for victims of NECC manufacturing problems. Item

Vaccines News

> CDC warns H1N1 virus is causing severe flu in young adults. More

> Genocea files IPO papers in a bid to raise $75M for vaccine development. Story

> Falsified AIDS vaccine data lands researcher an NIH funding ban. Article

> New Chinese quality standards raise the risk of a hep B vaccine shortage. News

> Argos to test investor appetite for cancer vaccines with a $60M IPO. Report

> FIT Biotech is set to start a Phase III HIV vaccine trial. Item

And Finally... Does vitamin E help people with Alzheimer's disease? One new study suggests a benefit. Report (sub. req.)

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.